Skip to main content
. 2017 Jul-Aug;33(4):886–890. doi: 10.12669/pjms.334.12647

Table-II.

Antimicrobial sensitivity of ESBL-producing E. coli.

Antibiotics Sensitive n (%) Intermediate n (%) Resistant n (%)
Amikacin (30µg) 68 (92.0) 0 (0.0) 6 (8.0)
Moxifloxacin (5µg) 44 (60.0) 0 (0.0) 30 (40.0)
Co-amoxiclav (20/10µg) 0 (0.0) 0 (0.0) 74 (100.0)
Ceftazidime (30µg) 0 (0.0) 0 (0.0) 74 (100.0)
Ceftriaxone (30µg) 0 (0.0) 0 (0.0) 74 (100.0)
Cefotaxime (30µg) 0 (0.0) 0 (0.0) 74 (100.0)
Cefuroxime (30µg) 0 (0.0) 0 (0.0) 74 (100.0)
Cefixime (5µg) 0 (0.0) 0 (0.0) 74 (100.0)
Cefoperazone-sulbactam (105µg) 74 (100.0) 0 (0.0) 0 (0.0)
Ciprofloxacin (5µg) 50 (67.0) 0 (0.0) 24 (33.0)
Piperacilin/tazobactam (100/10µg) 74 (100.0) 0 (0.0) 0 (0.0)
Meropenem (10µg) 67 (90.0) 0 (0.0) 7 (10.0)
Imipenem (10µg) 74 (100.0) 0 (0.0) 0 (0.0)